Skip to main content

Table 1 Clinical characteristics of asthmatic patients

From: Phosphodiesterase 3 inhibition and cough in elderly asthmatics

           

Treatment

Patient number

Age (yr)

Sex

Height (cm)

Type

Severity

Total IgE in serum (IU/ml)

Specific IgE in serum

Complication of allergic disease

RT20-FEV1 (mg/ml)*

Bronchodilator response (%)**

BDP (μg/day)

Theophylline (mg/day)

Clenbuterol (μg/day)

Carbocysteine (mg/day)

1

81

M

154

Int

Moderate

75

-

-

2.50

34.0

800

0

40

1500

2

72

F

151

Ext

Moderate

464

HD

AR

2.50

25.4

800

0

0

0

3

80

F

143

Ext

Moderate

3

Mite, HD

-

1.25

27.0

800

0

40

0

4

72

F

148

Int

Mild

28

-

-

0.08

19.4

0

0

0

1000

5

79

F

142

Int

Moderate

37

-

-

5.00

27.6

800

0

20

1500

6

72

F

150

Int

Moderate

57

-

-

0.31

22.3

400

0

40

0

7

72

F

147

Ext

Moderate

647

HD, Ceder

-

0.31

31.8

800

0

20

1500

8

70

F

140

Int

Moderate

17

-

-

1.25

17.6

800

0

40

1500

9

75

M

162

Ext

Moderate

148

HD, Ceder

AR

2.50

14.1

800

0

40

1500

10

71

M

165

Ext

Moderate

133

Mite, Ceder

AR

1.25

14.6

0

0

40

1500

11

80

M

165

Int

Moderate

2

-

-

2.50

12.6

400

0

0

0

  1. Ext, extrinsic; Int, intrinsic; HD, house dust; AR, allergic rhinitis; BDP, beclomethasone diproprionate inhalation.
  2. *PC20-FEV1 shows concentration of inhaled methacholine causing a 20% fall in FEV1.
  3. **Bronchodilator response means percent increase in forced expiratory volume in 1s (FEV1) from the baseline value after inhalation of 300 μg of salbutamol sulfate.
  4. All patients used inhaled β2-agonists (salbutamol or procaterol) on demand.